Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience ...

Biogen’s effort to buy Sage reveals its “desire to expand its pipeline at a discount,” according to analysts from BMO Capital ...

Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it's ...

Sage stock rose 35% to $7.51 in premarket trading Monday; it closed at $5.55 on Friday. Biogen shares dipped 0.5% to $48.01.

A yearslong partner of neuroscience player Sage, Biogen already owns 10.2% of the Cambridge, Massachusetts-based biotech, ...

Sage Therapeutics has a unique approach to targeting GABA, which allows it to target CNS disorders. Read why I think SAGE ...

Sage Therapeutics Inc. sued Biogen Inc. on Friday, a week after the biotech giant made an unsolicited offer to acquire the ...

Biogen’s proposed acquisition comes after two difficult years of regulatory and clinical challenges, during which shares of ...

Sage Therapeutics' financials indicate a need for additional funding in 2025, risking dilution and further financial ...

Biogen has been in the news recently after longtime partner Sage Therapeutics filed a lawsuit against the company after ...

The $7.22-per-share deal for 89.8% of Sage is a 30% premium on the company's share price on Friday and is estimated by ...

Meanwhile, Sage reported failed phase 2 trials of dalzanemdor in Alzheimer's, Parkinson's, and Huntington's disease, and ...